US Markets

Biogen plans trial to assess benefits of Spinraza after treatment with Zolgensma

Credit: REUTERS/BRIAN SNYDER

Biogen Inc said on Tuesday it plans to start a global clinical study to assess the safety and benefits of its spinal muscular atrophy drug Spinraza in children who were previously treated with Novartis AG's rival therapy Zolgensma.

July 21 (Reuters) - Biogen Inc BIIB.O said on Tuesday it plans to start a global clinical study to assess the safety and benefits of its spinal muscular atrophy drug Spinraza in children who were previously treated with Novartis AG's NOVN.S rival therapy Zolgensma.

The study aims at evaluating Spinraza to potentially improve clinical outcomes in some patients who do not respond sufficiently to the gene therapy Zolgensma, the company said. (https://reut.rs/3jsVIis)

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BIIB NOVN

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More